Connect
← Return to What if this prevents cancer from becoming resistant?
Discussion
What if this prevents cancer from becoming resistant?
Prostate Cancer | Last Active: 1 hour ago | Replies (76)Comment receiving replies
@surftohealth88 Looking closer, it probably wouldn't affect me, because my body (luckily) has managed long-term castrate-sensitivity. The BCL2 inhibitors maybe be able to help the ~10% of patients with a mutation that would otherwise have caused them to develop castrate-resistance faster than expected, in a few months, and may also be helpful (in a different way) after the development of castrate-resistance.
This is another example of how the research community keeps chipping away. There's no one big "Aha!" moment or cure like in the movies; instead, they just keep increasing the number of us who can keep on keeping on with metastatic prostate cancer, bit by bit, until some day we'll be the norm rather than the exception (if we're not there already).
Replies to "@surftohealth88 Looking closer, it probably wouldn't affect me, because my body (luckily) has managed long-term castrate-sensitivity...."
Connect
@northoftheborder
Oh yes, both articles are actually in context of future "personalized" approach to each case.
New research concentrates on discovering WHY some patients get to the point of resistance and why some can be on ADT for years without developing resistance. They discovered that there are different ways of how cells develop resistance since cells can have different mutations with the same end result - not having apoptosis and multiplying fast. That is why single approach can NOT be the answer. There will never be "one silver bullet" that would cover all patients especially in advanced cases.
I sent you those links since you like to read and analyze new research papers ; ), not necessarily thinking that they apply to your particular case - the point was that there is new research that is based on individualization of treatment for metastatic patients depending of the mutations that they poses.